I dagarna publicerades CRASH-3 i Lancet. Den handlar om effekten av TXA (tranexamsyra) till patienter med traumatisk hjärnskada.
Referenser
CRASH-1
Olldashi, F., Muzha, I., Filipi, N., Lede, R., Copertari, P., Traverso, C., … Muñoz-Sánchez, A. (2004). Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial. The Lancet. https://doi.org/10.1016/S0140-6736(04)17188-2

CRASH-2
CRASH-2 trial collaborators, Shakur, H., Roberts, I., Bautista, R., Caballero, J., Coats, T., … Yutthakasemsunt, S. (2010). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet (London, England), 376(9734), 23–32. https://doi.org/10.1016/S0140-6736(10)60835-5

CRASH-3
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (2019). The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(19)32233-0